



1645  
JH

PTO/SB/21 (04-04)


Approved for use through 07/31/2006. OMB 0651-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)		Application Number	09/833,017
		Filing Date	April 10, 2001
		First Named Inventor	Dennis Cvitkovitch
		Art Unit	1645
		Examiner Name	Padmavathi Baskar
Total Number of Pages in This Submission		Attorney Docket Number	1889-00401

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form  <input type="checkbox"/> Fee Attached  <input checked="" type="checkbox"/> Amendment/Reply  <input type="checkbox"/> After Final  <input checked="" type="checkbox"/> Declaration – Dr. Dennis Cvitkovitch  <input type="checkbox"/> Extension of Time Request  <input type="checkbox"/> Express Abandonment Request  <input type="checkbox"/> Information Disclosure Statement  <input type="checkbox"/> Certified Copy of Priority Document(s)  <input type="checkbox"/> Response to Missing Parts/ Incomplete Application  <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s)  <input type="checkbox"/> Licensing-related Papers  <input type="checkbox"/> Petition  <input type="checkbox"/> Petition to Convert to a Provisional Application  <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address  <input type="checkbox"/> Terminal Disclaimer  <input type="checkbox"/> Request for Refund  <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group  <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences  <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)  <input type="checkbox"/> Proprietary Information  <input type="checkbox"/> Status Letter  <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):  • Postcard
Remarks	Declaration Attachments:	
<p>(1) <u>Computational Differences between GbpC and CSP, NCBI database</u> (<a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a>) search results as of September 11, 2003</p> <p>(2) <u>BlastP Analysis of the CSP peptide against the whole S. Mutans UA159 Protein</u> <u>Database, posted date June 2, 2004</u></p> <p>(3) <u>Yutaka Sato et al., Cloning and Sequence Analysis of the gbpC Gene Encoding a</u> <u>Novel Glucan-Binding Protein of Streptococcus mutans, INFECTION AND IMMUNITY,</u> <u>Feb. 1997, p. 668-675</u></p> <p>(4) <u>K. Nakano et al., Attenuation of Glucan-binding Protein C Reduces the Cariogenicity</u> <u>of Streptococcus mutans: Analysis of Strains Isolated from Human Blood, J DENT</u> <u>RES, 2002, 81(6): 376-379</u></p>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Or Individual Name	Carol G. Mintz		
Signature			
Date	June 4, 2004		
CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or Printed Name	Fran Hampton		
Signature		Date	June 4, 2004



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 09/833,017  
Applicants : Dennis Cvitkovitch et al.  
Filed : April 10, 2001  
For : Signal Peptides, Nucleic Acid Molecules and  
Methods for Treatment of Caries

Confirmation No. 8365

TC/A.U. : 1645  
Examiner : Padmavathi Baskar

Atty. Dkt. No.: 1889-00401  
Date: June 4, 2004

**AMENDMENT AND RESPONSE TO OFFICE ACTION DATED MARCH 4, 2004**

Mail Stop AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Please amend the above-identified application as follows:

**Amendments to the Claims** are reflected in the listing of claims, which begins on page 2 of this paper.

**Remarks/Arguments** begin on page 4 of this paper.